{
    "clinical_study": {
        "@rank": "102445", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence."
            }, 
            {
                "arm_group_label": "Chlorthalidone 12.5 mg", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence."
            }, 
            {
                "arm_group_label": "Hydrochlorothiazide 25 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence."
            }
        ], 
        "brief_summary": {
            "textblock": "Chlorthalidone will result in improved endothelial function compared to hydrochlorothiazide\n      as measured by flow mediated vasodilatation."
        }, 
        "brief_title": "Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, double-blind, crossover study to evaluate chlorthalidone and\n      hydrochlorothiazide and their effects on endothelial function in hypertensive patients.\n      Subjects will receive chlorthalidone 12.5 mg, hydrochlorothiazide 25 mg, and placebo each\n      for 4 weeks with a 1 week washout between study periods.  Sequence of study drugs will be\n      randomized. Flow mediated vasodilatation will be measured at baseline and after each\n      treatment period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 19 or older\n\n          -  Diagnosis of hypertension\n\n          -  Current blood pressure > 120/80 mm Hg\n\n        Exclusion Criteria:\n\n          -  Use of a thiazide-type diuretic within the last 1 month\n\n          -  Known allergy to any study medications\n\n          -  History of gout or hyperuricemia\n\n          -  SCr >/= 1.8 mg/dl or CrCl < 25 ml/min\n\n          -  Pregnancy or breastfeeding or planning to become pregnant during study period\n\n          -  Dementia or cognitive impairment\n\n          -  Hypokalemia\n\n          -  Acute coronary syndrome or stroke within 6 months\n\n          -  Current use of sildenafil, tadalafil, or vardenafil"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01822860", 
            "org_study_id": "13-16628"
        }, 
        "intervention": [
            {
                "arm_group_label": "Chlorthalidone 12.5 mg", 
                "intervention_name": "Chlorthalidone 12.5 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Hydrochlorothiazide 25 mg", 
                "intervention_name": "Hydrochlorothiazide 25 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chlorthalidone", 
                "Hydrochlorothiazide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hypertension", 
            "Endothelial dysfunction"
        ], 
        "lastchanged_date": "April 1, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Omaha", 
                    "country": "United States", 
                    "state": "Nebraska", 
                    "zip": "68131"
                }, 
                "name": "Creighton University"
            }, 
            "investigator": {
                "last_name": "Ahmed Aboeata, MBBCh", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "The Effect of Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function in Hypertensive Patients: A Pilot Study", 
        "overall_contact": {
            "email": "tammyburns@creighton.edu", 
            "last_name": "Tammy L Burns, PharmD", 
            "phone": "402-280-4566"
        }, 
        "overall_official": {
            "affiliation": "Creighton University", 
            "last_name": "Ahmed Aboeata, MBBCh", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Flow mediated vasodilatation will be measured after one month on each drug and placebo", 
            "measure": "Flow mediated vasodilatation", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01822860"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Creighton University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Creighton University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}